DarioHealth Analyst Price Targets - Benzinga

DarioHealth Corp

DRIONASDAQ

Trade with Public

Trade with Public

$6.80

-0.18-2.58%

Dern. MÀJ: Aug 28, 9:28 AM

Aperçu Actualités Prévisions de résultatsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Rapport sur les stocks

DarioHealth Analyst Price Targets

Wall Street analyst price targets and consensus rating for DarioHealth (DRIO).

Price Target Range — 6 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$8Upside to Avg. PT+21.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 19, 2026	Alliance Global Partners	Scott Henry	Initiate	Buy	$12
Aug 12, 2026	TD Cowen	Charles Rhyee	PT Cut	Hold	$11→$8
May 14, 2026	Stifel	David Grossman	Maintained	Buy	$10
May 13, 2026	TD Cowen	Charles Rhyee	Maintained	Hold	$11
Mar 20, 2026	Stifel	David Grossman	PT Cut	Buy	$16→$10
May 19, 2025	Litchfield Hills	Theodore O'Neill	Initiate	Buy	$3
Mar 11, 2025	Stifel	David Grossman	PT Cut	Buy	$4→$2
Apr 1, 2024	Stifel	David Grossman	Maintained	Buy	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Alliance Global Partners Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $12

Alliance Global Partners analyst Scott Henry initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8

TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.

Benzinga Newsdesk

PRO
Litchfield Hills Initiates Coverage On DarioHealth with Buy Rating, Announces Price Target of $3

Litchfield Hills analyst Theodore O'Neill initiates coverage on DarioHealth (NASDAQ:DRIO) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
Stifel Maintains Buy on DarioHealth, Lowers Price Target to $2

Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $3.5 to $2.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on DarioHealth, Maintains $4 Price Target

Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and maintains $4 price target.

Benzinga Newsdesk